MA51284A - Dérivés d'oxadiazole en tant qu'inhibiteurs de kinase rho - Google Patents
Dérivés d'oxadiazole en tant qu'inhibiteurs de kinase rhoInfo
- Publication number
- MA51284A MA51284A MA051284A MA51284A MA51284A MA 51284 A MA51284 A MA 51284A MA 051284 A MA051284 A MA 051284A MA 51284 A MA51284 A MA 51284A MA 51284 A MA51284 A MA 51284A
- Authority
- MA
- Morocco
- Prior art keywords
- oxadiazole derivatives
- rho inhibitors
- kinase
- kinase rho
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17208187 | 2017-12-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA51284A true MA51284A (fr) | 2021-05-26 |
Family
ID=60673853
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA051284A MA51284A (fr) | 2017-12-18 | 2018-12-12 | Dérivés d'oxadiazole en tant qu'inhibiteurs de kinase rho |
Country Status (4)
Country | Link |
---|---|
US (1) | US11578068B2 (fr) |
EP (1) | EP3728247B1 (fr) |
MA (1) | MA51284A (fr) |
WO (1) | WO2019121233A1 (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4263548A1 (fr) | 2020-12-15 | 2023-10-25 | Chiesi Farmaceutici S.p.A. | Dérivés de dihydrofuropyridine en tant qu'inhibiteurs de la rho-kinase |
CA3202126A1 (fr) | 2020-12-15 | 2022-06-23 | Fabio Rancati | Derives de dihydrofuropyridine utilises comme inhibiteurs de la rho kinase |
AU2021402528A1 (en) | 2020-12-15 | 2023-07-27 | Chiesi Farmaceutici S.P.A. | Dihydrofuropyridine derivatives as rho- kinase inhibitors |
WO2023110700A1 (fr) | 2021-12-13 | 2023-06-22 | Chiesi Farmaceutici S.P.A. | Dérivés de dihydrofuropyridine utilisés comme inhibiteurs de la rho-kinase |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7737153B2 (en) | 2002-10-28 | 2010-06-15 | Bayer Schering Pharma Aktiengesellschaft | Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors |
DE102004017438A1 (de) | 2004-04-08 | 2005-11-03 | Bayer Healthcare Ag | Hetaryloxy-substituierte Phenylaminopyrimidine |
WO2006009889A1 (fr) | 2004-06-17 | 2006-01-26 | Smithkline Beecham Corporation | Inhibiteurs novateurs de protéines rho-kinases |
US20110207704A1 (en) * | 2006-12-15 | 2011-08-25 | Abbott Laboratories | Novel Oxadiazole Compounds |
CA2709918A1 (fr) | 2007-12-21 | 2009-06-25 | The Scripps Research Institute | Benzopyranes et analogues utilises comme inhibiteurs de la rho kinase |
EP2331507A2 (fr) | 2008-09-18 | 2011-06-15 | Astellas Pharma Inc. | Composés de carboxamide hétérocycliques |
ES2622519T3 (es) | 2010-07-14 | 2017-07-06 | Novartis Ag | Componentes heterocíclicos agonistas del receptor IP |
US9682963B2 (en) | 2013-01-29 | 2017-06-20 | Redx Pharma Plc | Pyridine derivatives as soft rock inhibitors |
AR110401A1 (es) | 2016-12-21 | 2019-03-27 | Chiesi Farm Spa | Derivados dihidropirimidina bicíclica-carboxamida como inhibidores de rho-quinasa |
WO2018138293A1 (fr) | 2017-01-30 | 2018-08-02 | Chiesi Farmaceutici S.P.A. | Dérivés de tyrosine amide utilisés en tant qu'inhibiteurs de la rho-kinase |
-
2018
- 2018-12-12 MA MA051284A patent/MA51284A/fr unknown
- 2018-12-12 US US16/954,968 patent/US11578068B2/en active Active
- 2018-12-12 WO PCT/EP2018/084548 patent/WO2019121233A1/fr unknown
- 2018-12-12 EP EP18829255.1A patent/EP3728247B1/fr active Active
Also Published As
Publication number | Publication date |
---|---|
EP3728247B1 (fr) | 2021-09-22 |
US11578068B2 (en) | 2023-02-14 |
WO2019121233A1 (fr) | 2019-06-27 |
EP3728247A1 (fr) | 2020-10-28 |
US20200331912A1 (en) | 2020-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA47125A (fr) | Dérivés de pyrazole en tant qu'inhibiteurs de malt1 | |
MA52486A (fr) | Pyridazinones utilisés en tant qu'inhibiteurs de parp7 | |
MA48994A (fr) | Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1 | |
MA51429A (fr) | Dérivés amino-fluoropipéridines utilisés en tant qu'inhibiteur de kinase | |
MA49013A (fr) | Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2 | |
MA40774A (fr) | Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38 | |
MA47123A (fr) | Dérivés de benzooxazole en tant qu'mmunomodulateurs | |
MA45189A (fr) | Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2 | |
MA47460A (fr) | Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase | |
MA47013A (fr) | Composés benzolactames utilisés en tant qu'inhibiteurs de protéine kinase | |
MA54547A (fr) | Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a | |
MA54546A (fr) | Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a | |
MA46339A (fr) | Dérivés de cyanopyrrolidine ayant une activité en tant qu'inhibiteurs de l'usp 30 | |
DK3656769T3 (da) | Aryl-phosphor-oxygen-forbindelse som egfr-kinase-inhibitor | |
DK3522715T3 (da) | Mikrobiocide oxadiazolderivativer | |
MA45244A (fr) | Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1 | |
MA51878A (fr) | Composés d'aminothiazole en tant qu'inhibiteurs de c-kit | |
MA51431A (fr) | Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase | |
MA43169A (fr) | Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma | |
MA46981A (fr) | Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine | |
MA50456A (fr) | Formulations d'un inhibiteur de kinase trk macrocyclique | |
MA42659A (fr) | Dérivés hétéroaryle utilisés en tant qu'inhibiteurs de parp | |
MA45153A (fr) | Dérivés de carbonucléosides substitués utiles en tant qu'agents anticancéreux | |
MA47086A (fr) | Dérivés de dihydropyrimidine-carboxamide bicycliques utilisés en tant qu'inhibiteurs de rho-kinase | |
MA51433A (fr) | Dérivé d'amino-méthyl pipéridine en tant qu'inhibiteur de kinase |